capecitabine has been researched along with Peripheral Nerve Diseases in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (36.21) | 29.6817 |
| 2010's | 29 (50.00) | 24.3611 |
| 2020's | 8 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Bando, H; Eto, T; Hasegawa, J; Horiuchi, T; Kato, T; Kotaka, M; Manaka, D; Misumi, T; Mizushima, T; Mori, M; Munemoto, Y; Nakamura, F; Nakamura, M; Nishi, M; Ohtsu, A; Oki, E; Sakamoto, J; Sakamoto, Y; Shiozawa, M; Takagane, A; Taniguchi, H; Yamagishi, H; Yoshino, T | 1 |
| Choi, GE; Jang, A; Jin, H; Ju, Y; Kim, J; Seol, YM | 1 |
| Emoto, S; Ishihara, S; Murono, K; Nozawa, H; Okamoto, K; Sasaki, K | 1 |
| Barreda-Hernández, D; Fernández-Carballido, AM; Sánchez-Gundín, J; Torres-Suárez, AI | 1 |
| Bando, H; Eto, T; Gamoh, M; Hasegawa, J; Kato, T; Kotaka, M; Maehara, Y; Manaka, D; Mizushima, T; Mori, M; Munemoto, Y; Nakamura, M; Ohtsu, A; Oki, E; Saji, S; Shiozawa, M; Takagane, A; Takeuchi, S; Taniguchi, H; Yamanaka, T; Yoshino, T | 1 |
| Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW | 1 |
| Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T | 1 |
| Chen, H; Lu, Y; Xu, C; Xu, L; Yao, Q; Yao, W; Zhang, L; Zhang, R; Zhang, X | 1 |
| Coupé, VMH; Greuter, MJE; Jongeneel, G; Koopman, M; Punt, CJA; Twisk, JWR; van Erning, FN; Vink, GR | 1 |
| Gui, Q; Li, D; Xu, C; Zhuge, Y | 1 |
| Hasegawa, H; Kitagawa, Y; Kitahama, K; Kojima, K; Murai, S; Oto, I; Ozawa, H; Tajima, Y; Takenoya, T; Tamura, E; Yabe, N; Yoshikawa, T | 1 |
| Aapro, M; Bondarenko, I; Campone, M; Krishnamurthy, S; Lebedeva, L; Martin, M; Roman, L; Sakaeva, D; Vedovato, JC | 1 |
| Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C | 1 |
| Brinch, CM; Ekblad, L; Hermann, KL; Holm, VH; Jensen, BK; Jensen, BV; Larsen, FO; Lindgaard, SC; Michelsen, H; Nelausen, KM; Nielsen, DL; Nørgaard, HH; Soerensen, PG; Theile, S | 1 |
| Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM | 1 |
| Coley, H; Kadakia, KC; Salem, ME; Worrilow, WM | 1 |
| Alberti, P; Angelopoulou, A; Antonacopoulou, A; Argyriou, AA; Briani, C; Bruna, J; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Genazzani, AA; Kalofonos, HP; Lonardi, S; Psaromyalou, A; Santos, C; Terrazzino, S; Velasco, R | 1 |
| Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE | 1 |
| Beijers, AJ; Faber, CG; Mols, F; Tjan-Heijnen, VC; van de Poll-Franse, LV; Vreugdenhil, G | 1 |
| Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R | 1 |
| Fahimi, A; Payandeh, M; Sadeghi, M; Shahriari-Ahmadi, A | 1 |
| Avallone, A; Capozzi, M; Capuozzo, M; Casaretti, R; Cassata, A; De Divitiis, C; Iaffaioli, VR; Maiolino, P; Nappi, A; Nasti, G; Ottaiano, A; Quagliariello, V; Romano, C; Scala, S; Silvestro, L; Tafuto, S | 1 |
| Dimopoulos, MA; Karandreas, N; Kokotis, P; Kostouros, E; Schmelz, M | 1 |
| Beijers, TAJM; Janssen-Heijnen, MLG; Lemmens, VEPP; Slooter, GD; van de Poll-Franse, LV; van Erning, FN; Vreugenhil, A; Wegdam, JA; Wijsman, JH | 1 |
| Inukai, M; Nagasaka, T; Okajima, M; Tanioka, H; Toyota, K; Tsuji, A; Tsuruta, A; Yamakawa, T; Yamano, T; Yamashita, K; Yamatsuji, T; Yoshimitsu, M | 1 |
| Frye, DK | 1 |
| Boehnke Michaud, L | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Dong, NN; Liu, ZF; Wang, MY; Zhang, Q | 1 |
| Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P | 1 |
| Clive, S; Dawson, LK; Fallon, MT; McLean, CM; Phillips, HA; Sakala, M; Storey, DJ; Wall, LR | 1 |
| Stein, A | 1 |
| Fan, Y; Wang, J; Xu, B | 1 |
| Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B | 1 |
| Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Egerton, N | 1 |
| Arkenau, HK | 1 |
| Feng, M; Qiu, F; Xiang, XJ; Xiong, JP; Yan, J; Yu, F; Zhan, ZY; Zhang, L; Zhao, JG | 1 |
| Bunnell, CA; Fornier, MN; Hortobagyi, GN; Martín, M; Mukhopadhyay, P; Peck, RA; Perez, EA; Roché, HH; Sparano, JA; Thomas, ES; Vahdat, LT; Yelle, L | 1 |
| Ahn, JB; Hong, YS; Im, SA; Jung, KH; Kang, YK; Kim, JH; Kim, KP; Kim, TW; Kim, TY; Lee, JL; Lee, SS; Park, YS; Shin, SJ | 1 |
| Ji, T; Jiao, S; Yang, J; Zhu, Y | 1 |
| Twelves, C | 1 |
| Ayers, GD; Lin, E; Morris, JS | 1 |
| Begbie, S; Borner, M; Burns, WI; Burris, HA; Cassidy, J; Garcia-Alfonso, P; Jodrell, D; Koralewski, P; Levine, EL; Maroun, J; Marschner, N; McKendrick, J; Scheithauer, W; Tujakowski, J; Twelves, C; Van Hazel, G; Wong, A; Zaluski, J | 1 |
| Hahn, P; Jensen, HA; Pfeiffer, P | 1 |
| Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N | 1 |
| Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ | 1 |
| Diasio, RB; McGee, PJ; Saif, MW; Wood, TE | 1 |
| Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J | 1 |
| Hildebrand, J | 1 |
| Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C | 1 |
| Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R | 1 |
| Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D | 1 |
| Floeter, MK; Grem, JL; Lehky, T; Quinn, MG; Thomas, RR; Wilson, RH | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
7 review(s) available for capecitabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Paresthesia; Patient Compliance; Patient Education as Topic; Peripheral Nervous System Diseases; Prodrugs | 2009 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Premedication; Tubulin Modulators | 2009 |
Interaction between capecitabine and brivudin in a patient with breast cancer.
Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Bromodeoxyuridine; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Fatal Outcome; Female; Fluorouracil; Herpes Zoster; Humans; Onycholysis; Palliative Care; Peripheral Nervous System Diseases; Salvage Therapy; Stomatitis; Tooth Discoloration | 2010 |
Ixabepilone.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Epothilones; Female; Fluorouracil; Humans; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Hospitalization; Humans; Leucovorin; Multicenter Studies as Topic; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prodrugs | 2002 |
Neurological complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Neoplasms; Neuroprotective Agents; Peripheral Nervous System; Peripheral Nervous System Diseases; Vitamin E | 2006 |
27 trial(s) available for capecitabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies | 2022 |
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Peripheral Nervous System Diseases | 2019 |
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorouracil; G(M1) Ganglioside; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Placebos; Severity of Illness Index | 2020 |
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Treatment Outcome | 2020 |
Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Omega-3; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neurotoxicity Syndromes; Oxaliplatin; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires | 2020 |
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Exercise Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases | 2021 |
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Progression-Free Survival; Quality of Life; Survival Analysis; Taxoids; Vinblastine | 2018 |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Quality of Life; Survival Rate; Time Factors | 2018 |
Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoembolization, Therapeutic; Fatigue; Female; Hand-Foot Syndrome; Hepatic Artery; Humans; Liver Neoplasms; Middle Aged; Oxaliplatin; Peripheral Nervous System Diseases; Progression-Free Survival | 2019 |
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Motor Neurons; Neoplasm Staging; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Risk Factors; Sensory Receptor Cells; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2016 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxaloacetates; Peripheral Nervous System Diseases; Remission Induction; Stomach Neoplasms; Survival Rate | 2009 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; China; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Retreatment; Taxoids | 2010 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Stomach Neoplasms; Survival Rate; Thrombocytopenia; Vomiting | 2012 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Republic of Korea; Thrombocytopenia; Treatment Outcome | 2014 |
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; G(M1) Ganglioside; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Sialic Acids; Treatment Outcome; Young Adult | 2013 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Safety | 2003 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Nausea; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Treatment Outcome; Vomiting | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Treatment Outcome | 2004 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2004 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Pain; Peripheral Nervous System Diseases; Pyrazoles; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Rate | 2008 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, Liquid; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Mass Spectrometry; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Peripheral Nervous System Diseases | 2001 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
24 other study(ies) available for capecitabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Expression Profiles of Circulating MicroRNAs in XELOX-Chemotherapy-Induced Peripheral Neuropathy in Patients with Advanced Gastric Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Circulating MicroRNA; Gene Expression Profiling; Humans; MicroRNAs; Oxaloacetates; Peripheral Nervous System Diseases; Stomach Neoplasms | 2022 |
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Quality of Life | 2023 |
Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Compounding; Drugs, Generic; Female; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Male; Middle Aged; Mucositis; Neutropenia; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies; Thrombocytopenia | 2019 |
Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study.
Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Clinical Decision-Making; Colorectal Neoplasms; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Treatment Outcome | 2021 |
[A Case of Phrenic Nerve Paralysis During Adjuvant Chemotherapy for Rectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Paralysis; Peripheral Nervous System Diseases; Phrenic Nerve; Rectal Neoplasms | 2017 |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires | 2019 |
Optimal duration of adjuvant therapy for stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Levamisole; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Prognosis; Prospective Studies; Risk; Treatment Outcome | 2019 |
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Incidence; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Voltage-Gated Sodium Channels | 2013 |
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperature; Colorectal Neoplasms; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Liver Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prognosis; Retrospective Studies | 2014 |
Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Peripheral Nervous System Diseases; Quality of Life; Registries; Risk; Sex Factors; Survivors | 2015 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Prospective Studies; Recovery of Function | 2014 |
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypercalciuria; Iran; Leucovorin; Male; Middle Aged; Nephrocalcinosis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Renal Tubular Transport, Inborn Errors; Risk Factors | 2015 |
Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Capecitabine; Chemotherapy, Adjuvant; Chronic Disease; Colonic Neoplasms; Diabetes Complications; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Obesity; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prognosis | 2016 |
Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2016 |
The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A Longitudinal Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Humans; Longitudinal Studies; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2017 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Incidence; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies; Scotland | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2011 |
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Peripheral Nervous System Diseases; Proportional Hazards Models; Risk Factors; Severity of Illness Index; Time Factors; Tubulin Modulators; Young Adult | 2012 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Hypoxia; Isoenzymes; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Peripheral Nervous System Diseases; Prodrugs; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Syndrome | 2002 |
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies | 2003 |
Peripheral neuropathy associated with capecitabine.
Topics: Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Female; Fluorouracil; Forecasting; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prodrugs | 2004 |
Acute oxaliplatin-induced peripheral nerve hyperexcitability.
Topics: Acute Disease; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbamazepine; Clinical Trials, Phase I as Topic; Deoxycytidine; Electromyography; Female; Fluorouracil; Humans; Isaacs Syndrome; Male; Middle Aged; Neural Conduction; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Treatment Failure | 2002 |